Larimar Therapeutics, Inc. LRMR 深 沪
交易中 09-30 10:51:23 美东时间
3.135
-0.005
-0.16%
华盛通- 最 高3.17
- 今 开3.13
- 成交量 25.50万股
- 最 低 3.075
- 昨 收 3.14
- 总市值 3.26亿
- 52周最高 6.42
- 市盈率 静 --
- 换手率 0.25%
- 52周最低 2.715
- 委 比 -27.97%
- 总股本 1.04亿
- 历史最高 664.32
- 量 比 0.62
- 振 幅 3.03%
- 历史最低 1.53
- 每 手 1
- 风险率 0.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Larimar Therapeutics Appoints John Harlow As President and COO, Effective September 29
Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon...
今天 04:06
Century Therapeutics Appoints Joseph Truitt to Board of Directors
Century Therapeutics appoints Joseph Truitt to its Board of Directors. Truitt, CEO of iECURE and Chairman of Larimar Therapeutics, brings extensive leadership experience in biotech. Century is advancing CNTY-813, an iPSC-derived therapy for type 1 diabetes, toward IND submission, and CNTY-308, a CAR-iT cell therapy for B-cell diseases, toward clinical entry, both leveraging its Allo-Evasion™ platform.
09-09 20:05
Larimar’s CTI-1601 Study Update Keeps Friedreich’s Ataxia Catalyst in Play
Larimar Therapeutics, Inc. ($LRMR) announced an update on their ongoing clinica...
09-04 00:32
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $12 to $11.
08-05 21:24
Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 26.83 percent increase over losses of $(0.41) per share from the same period last year.
08-04 19:12
美股牛股 | 生物制药公司FBRX大涨逾78%！关键药物研究成果积极；地热电力公司FRVO股价劲升16%
生物制药公司FBRX大涨逾78%！关键药物研究成果积极；地热电力公司FRVO股价劲升16%，地热开发项目取得重要进展；贵金属概念股TXG涨15%！此前获大摩大幅上调目标价>>
07-10 19:22
Larimar Therapeutics shares are trading higher after a Form 4 filing indicated that a Director bought 50K shares at an average price of $3.34 per share.
Larimar Therapeutics shares are trading higher after a Form 4 filing indicated that a Director bought 50K shares at an average price of $3.34 per share.
07-10 02:20
美股大行评级 | Bernstein上调闪迪目标价从1700美元升至3000美元；大摩上调谷歌-A目标价从375美元升至415美元
今日重点评级关注：Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元；康托·菲茨杰拉德：维持BioCryst制药"超配"评级，目标价从27美元升至29美元
07-01 10:40
分析师解读医疗企业 Replimune Group（REPL）、Abivax SA 担保ADR（ABVX）及Larimar Therapeutics（LRMR）
3位医疗领域五星分析师近期分别对3只美股医疗保健个股给出看涨评级，相关核心信息如下： Replimune Group（REPL）：摩根大通将其评级上调至买入...
06-30 22:02
